Radiotherapy at ESMO: expanding indications around anchor targets
Novartis builds its case for Pluvicto in earlier-line mCRPC, while Rayze and Convergent test α-emitters in patients who progressed on β-emitters
Data at ESMO highlight how Novartis and other targeted radiopharmaceuticals players are expanding the indication opportunities for the field’s two established tumor targets, PSMA and SSTR2, as the pharma contends with the overall survival analysis challenge common across oncology.
In its Oct. 24 earnings report, Novartis AG (SIX:NOVN; NYSE:NVS) said confounding effects on overall survival (OS) from patient crossovers in its Phase III PSMAfore trial would delay a submission to FDA to take the PSMA-targeted radiotherapy Pluvicto Lu177 vipivotide tetraxetan into an earlier line of metastatic castration-resistant prostate cancer (mCRPC), despite the therapy’s consistent benefit on radiographic progression-free survival (rPFS). The company had previously planned to seek regulatory approval before year-end...